Hazlett Burt & Watson Inc. Raises Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Hazlett Burt & Watson Inc. increased its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 98.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 342 shares of the medical equipment provider’s stock after purchasing an additional 170 shares during the quarter. Hazlett Burt & Watson Inc.’s holdings in Intuitive Surgical were worth $154,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in ISRG. One Wealth Management Investment & Advisory Services LLC grew its stake in shares of Intuitive Surgical by 3.4% during the 2nd quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider’s stock worth $310,000 after purchasing an additional 23 shares during the period. Indiana Trust & Investment Management CO grew its stake in Intuitive Surgical by 5.3% in the 2nd quarter. Indiana Trust & Investment Management CO now owns 500 shares of the medical equipment provider’s stock valued at $222,000 after acquiring an additional 25 shares during the period. Hoxton Planning & Management LLC grew its stake in Intuitive Surgical by 4.9% in the 2nd quarter. Hoxton Planning & Management LLC now owns 534 shares of the medical equipment provider’s stock valued at $238,000 after acquiring an additional 25 shares during the period. First Affirmative Financial Network grew its stake in Intuitive Surgical by 2.7% in the 2nd quarter. First Affirmative Financial Network now owns 996 shares of the medical equipment provider’s stock valued at $443,000 after acquiring an additional 26 shares during the period. Finally, Advance Capital Management Inc. grew its stake in Intuitive Surgical by 3.8% in the 1st quarter. Advance Capital Management Inc. now owns 740 shares of the medical equipment provider’s stock valued at $295,000 after acquiring an additional 27 shares during the period. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on ISRG shares. JPMorgan Chase & Co. lifted their price target on shares of Intuitive Surgical from $475.00 to $495.00 and gave the company an “overweight” rating in a research note on Friday, July 19th. Evercore ISI dropped their price target on shares of Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating on the stock in a research note on Friday, July 19th. Stifel Nicolaus lifted their price target on shares of Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a research note on Friday, July 19th. Robert W. Baird raised their price objective on Intuitive Surgical from $487.00 to $503.00 and gave the company an “outperform” rating in a report on Friday, July 19th. Finally, Piper Sandler raised their price objective on Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a report on Friday, July 19th. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $446.45.

Insider Buying and Selling

In other Intuitive Surgical news, SVP Henry L. Charlton sold 40,243 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $486.84, for a total value of $19,591,902.12. Following the sale, the senior vice president now owns 3,001 shares of the company’s stock, valued at $1,461,006.84. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, SVP Henry L. Charlton sold 40,243 shares of the business’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $486.84, for a total value of $19,591,902.12. Following the sale, the senior vice president now owns 3,001 shares in the company, valued at approximately $1,461,006.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Amal M. Johnson sold 2,943 shares of the firm’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $443.30, for a total value of $1,304,631.90. Following the transaction, the director now owns 12,275 shares of the company’s stock, valued at $5,441,507.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 50,555 shares of company stock valued at $24,267,737. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Stock Up 1.4 %

NASDAQ:ISRG opened at $490.93 on Thursday. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $493.97. The stock’s fifty day moving average is $461.63 and its two-hundred day moving average is $420.33. The company has a market capitalization of $174.13 billion, a P/E ratio of 88.62, a P/E/G ratio of 5.20 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.24. The firm had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. Intuitive Surgical’s revenue was up 14.5% on a year-over-year basis. During the same period in the previous year, the firm earned $1.18 EPS. Sell-side analysts anticipate that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.